STOK
Stoke Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$26.29Close
$1.5BMarket cap
$22.37 – $38.3552-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 21 · weaker than 79% of stocks over 12 months
- Far from its high 31% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
31%
1wk
up 5.0%
price change
1mo
up 1.1%
price change
12-month return
down 17%
market up 11% ·
its own down 27%
F-score
—
— Not assessed
Altman Z
13.41
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.4×
price / book
Earnings yield
down 1.4%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
up 405%
year on year
EPS growth
—
latest quarter
Sales growth
down 33%
latest quarter · +64 pts
ROE
down 2%
return on equity
Free cash margin
up 24%
$44.9M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
Repair signals
- FCF turned positive ($-87M → $45M)
Trade setup
ATR%
4.7%
$1.22 a day · 2×ATR $23.84
RS
21 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.8×
vs 50-day average
Up/down volume
0.75
50 sessions
Implied move
—
no scheduled report
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 9.0% over the year, from 54m to 59m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026+2% vs market2 sessions after results
Financials
- Net -4%
- Free cash 24%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $12.4M | $8.8M | $36.6M | $184.4M |
| Operating income | -$53.0M | -$86.1M | -$104.4M | -$114.8M | -$101.4M | -$20.6M |
| Net income | -$52.2M | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
| Net margin | — | — | -815% | -1192% | -243% | -4% |
| Earnings per share | — | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
| Free cash flow | -$43.3M | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M |
| Free cash margin | — | — | -289% | -942% | -238% | 24% |
| Cash | $287.3M | $144.9M | $113.6M | $191.4M | $128.0M | $84.2M |
| Shareholders' equity | $286.1M | $217.8M | $184.8M | $159.6M | $229.0M | $352.5M |
| Shares outstanding | 36.58m | 36.90m | 39.44m | 45.92m | 54.03m | 58.92m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 3, 2026 | Quarterly ↗ | Jun 30, 2026 | 34d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 16, 2026 | Annual ↗ | Dec 31, 2025 | 75d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Mar 25, 2024 | Annual ↗ | Dec 31, 2023 | 85d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results ↗ |
| Sep 25, 2026 | Director or officer change ↗ |
| Aug 3, 2026 | Other events ↗ |
| Aug 3, 2026 | Results ↗ |
| Jun 30, 2026 | Regulation FD · Other events ↗ |
| Jun 4, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 7, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 27, 2026 | Auditor change ↗ |
| Mar 3, 2026 | Director or officer change ↗ |
| Jan 26, 2026 | Material agreement · New obligation ↗ |
| Jan 12, 2026 | Results · Regulation FD · Other events ↗ |